CoChat
Sign Up
Cited by 23Intracerebral and Subarachnoid Hemorrhage ResearchDementia and Cognitive Impairment ResearchCerebrovascular and genetic disorders

Pattern of and Risk Factors for Brain Microbleeds in Neurodegenerative Dementia

Open access
Olazarán, Javier, Ramos, Ana, Boyano, Inmaculada, Alfayate, Eva, Valentí, Meritxell, Rábano, Alberto, Álvarez-Linera, Juan·2014·American Journal of Alzheimer's Disease & Other Dementias®
DOI 10.1177/1533317513517043PMC PMC10852872
Open this paper in CoChat — free accountOpen PDF

Abstract

Objective: A cross-sectional study was conducted to describe the prevalence, locations, and risk factors for brain microbleeds (BMBs) in neurodegenerative dementia. Methods: The database of the Alzheimer Center Reina Sofía Foundation was searched, BMBs were described, and the potential associations of BMBs were investigated using univariate statistics. Results: A total of 148 patients (age 81.6 [standard deviation 6.7], 79.1% female) were studied. Prevalence of BMBs was 44.6%. A group of patients with unusually high (ie, ≥4) number of BMBs were identified, which displayed higher number of vascular risk factors and vascular diseases. Brain microbleeds were also associated with ischemic lesions in the basal ganglia ( r = .39), clinical diagnosis of Alzheimer’s disease (AD) and cerebrovascular disease ( r = .33), cortical infarction ( r = .20), and antiaggregant or anticoagulant treatment duration ( r = .20). Conclusions: Brain microbleeds are associated with vascular burden and AD diagnosis in old patients with neurodegenerative dementia. More research is warranted regarding the mechanisms and potential clinical implications of these results.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1177/1533317513517043

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The broad range of detection of microbleeds could likely be attributed to the magnet field strength, with clinical strength 1.5 and 3T magnets likely underestimating the incidence of microbleeds compared with the research-grade 7T magnet.

    “This broad range of detection could likely be attributed to the magnet field strength, with clinical strength 1.5 and 3T magnets likely underestimating the incidence of microbleeds compared with the research-grade 7T magnet (83, 246, 452, 530, 604, 669).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [452]

    The Discussion (page unavailable) says earlier studies used 1.0-T or 1.5-T scanners and that this study’s 3.0-T scanner improved sensitivity for detecting brain microbleeds. It does not discuss 7T scanners or establish that both 1.5T and 3T underestimate detection relative to 7T; it also notes age and cerebrovascular disease as possible reasons for differing prevalence. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • CNS microbleeds reflect loss of cerebrovascular integrity and are found in 25% of individuals with MCI and 45-78% of individuals with early AD without dementia.

    “CNS microbleeds reflect loss of cerebrovascular integrity and are found in 25% of individuals with MCI (669) and 45-78% of individuals with early AD without dementia (83, 208, 246, 452, 476, 529, 604, 702).”

    From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [452]

    Citation 669 is attached to the claim that microbleeds occur in 25% of people with MCI. The Results report microbleeds in 44.6% of 148 patients with neurodegenerative dementia, not an MCI group. Searches for MCI and the 25% figure found no passage in our copy addressing that prevalence; the later AD figures have different citations. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 24

  1. Sveinbjornsdottir S, Sigurdsson S, Aspelund T, et al. Cerebral microbleeds in the population based AGES-Reykjavik study: prevalence and location. J Neurol Neurosurg Psychiatry. 2008; 79(9): 1002-1006.
  2. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design and reporting. Brain. 2007;130(pt 8):1988-2003.
  3. van Es AC, van der Grond J, de Craen AJ, et al. Cerebral micro- bleeds and cognitive functioning in the PROSPER study. Neurol- ogy. 2011;77(15):1446-1452.
  4. Poels MM, Ikram MA, van der Lugt A, et al. Cerebral micro- bleeds are associated with worse cognitive function: the rotterdam scan study. Neurology. 2012;78(5):326-333.
  5. Maxwell SS, Jackson CA, Paternoster L, et al. Genetic associations with brain microbleeds: systematic review and meta-analyses. Neurology. 2011;77(2):158-167.
  6. Altmann Schneider I, Trompet S, de Craen AJ, et al. Cerebral microbleeds are predictive of mortality in the elderly. Stroke. 2011;42(3):638-644.
  7. Panza F, Frisardi V, Imbimbo BP, Seripa D, Solfrizzi V, Pilotto A. Monoclonal antibodies against b-amyloid (Ab) for the treatment of Alzheimer's disease: the Ab target at a crossroads. Expert Opin Biol Ther. 2011;11(6):679-686.
  8. Martinez Martin P, Avila J, AD Research Unit Investigators. Alzheimer center reina sofia foundation: fighting the disease and providing overall solutions. J Alzheimers Dis. 2010;21(2): 337-348.
  9. Olazara ´n J, Agu ¨era-Ortiz L, Osorio R, et al. Promoting research in advanced dementia: early clinical results of the Alzheimer center reina sofı ´a foundation. J Alzheimers Dis. 2012;28(1): 211-222.
  10. Reisberg B, Ferris SH, de Leon MJ, Crook T. The global dete- rioration scale for assessment of primary degenerative dementia. Am J Psychiatry. 1982;139(9):1136-1139.
  11. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in 'probable' Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry. 1992;55(10):967-972.
  12. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke. 2001;32(6):1318-1322.
  13. Juniper EF, Guyatt GH, Jaeschke R. How to develop and vali- date a new health-related quality of life instrument. In B. Spilker, ed. Quality of Life and Pharmacoeconomics in Clin- ical Trials. Philadelphia, PA: Lippincott-Raven Publishers; 1996:49-56.
  14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzhei- mer's disease. Neurology. 1984;34(7):939-944.
  15. McKeith IG, Dickson DW, Lowe J, et al. Consortium on DLB. diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65(12): 1863-1872.
  16. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurol- ogy. 1998;51(6):1546-1554.
  17. Nandigam RN, Viswanathan A, Delgado P, et al. MR imaging detection of cerebral microbleeds: effect of susceptibility- weighted imaging, section thickness, and field strength. Am J Neuroradiol. 2009;30(2):338-343.
  18. Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. Addiction. 2002;97(1):15-28.
  19. Attems J, Quass M, Jellinger KA, Lintner F. Topographical distri- bution of cerebral amyloid angiopathy and its effect on cognitive decline are influenced by Alzheimer disease pathology. J Neurol Sci. 2007;257(1-2):49-55.
  20. Cullen KM, Ko ´csi Z, Stone J. Microvascular pathology in the aging human brain: evidence that senile plaques are sites of microhaemorrhages. Neurobiol Aging. 2006;27(12):1786-1796.
  21. Stone J. What initiates the formation of senile plaques? the origin of Alzheimer-like dementias in capillary haemorrhages. Med Hypotheses. 2008;71(3):347-359.
  22. van der Vlies AE, Goos JD, Barkhof F, Scheltens P, van der Flier WM. Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology. 2012;79(8):763-769.
  23. Rothman KJ. No adjustments are needed for multiple compari- sons. Epidemiology. 1990;1(1):43-46.
  24. Ku HL, Chi NF. Cerebral lobar microhemorrhages detection by high magnetic field susceptibility weighted image: a potential diagnostic neuroimage technique of Alzheimer's disease. Med Hypotheses. 2011;76(6):840-842.

Cited by

Sorted by citations

Authors
Olazarán, J., Ramos, A., Boyano, I., Alfayate, E., Valentí, M., Rábano, A., & Álvarez-Linera, J.
Affiliations
  • Instituto de Salud Carlos III (ES)
  • Hospital Universitario de Móstoles (ES)
  • Alzheimer Disease Research Unit, Alzheimer Center Reina Sofía Foundation—CIEN Foundation, Carlos III Institute of Health, Madrid, Spain
Corresponding author
Olazarán, Javier
ORCID
Venue
American Journal of Alzheimer's Disease & Other Dementias®
Publisher
SAGE Publications
Published
2014-01-08
Volume
29
Issue
3
Pages
263-269
ISSN
  • 0888-4897 (ISSN-L)
  • 1533-3175
  • 1938-2731
DOI
10.1177/1533317513517043
PMC
PMC10852872
OpenAlex
W2326683895
Cited by
23
References
1
Citations by year
2026: 1 · 2023: 2 · 2022: 4 · 2020: 1 · 2018: 4 · 2017: 1 · 2016: 1 · 2015: 6 · 2014: 3
FWCI
2.39
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • American Journal of Alzheimer s Disease & Other Dementias® (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Neurology › Intracerebral and Subarachnoid Hemorrhage Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Neurology › Cerebrovascular and genetic disorders
Keywords
cerebral microbleeds, neurodegenerative dementia, Alzheimer's disease, vascular risk factors, cerebrovascular disease, vascular burden, cortical infarction, prevalence, risk factors
MeSH terms
Aged, Aged, 80 and over, Alzheimer Disease, Cerebrovascular Disorders, Dementia, Female, Humans, Magnetic Resonance Imaging, Male, Risk Factors, Comorbidity, Neurodegenerative Diseases, Intracranial Hemorrhages

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review